that are readily available in clinical practice. Second, we examined the association between receipt of evidence-based care metrics during TIA hospitalization and risk of ischemic stroke during the year after hospital discharge. Finally, we examined whether the association between receipt of evidence-based care metrics during the initial TIA hospitalization and 1-year ischemic stroke varied by estimated ischemic stroke risk.
Methods
We used data from the Get With The Guidelines (GWTG)-Stroke program and Centers for Medicare and Medicaid Services (CMS). Details of the design and methods of GWTG-Stroke have been previously published. 18 Briefly, GWTG-Stroke is an ongoing national hospitalbased quality improvement initiative for patients with acute stroke. Trained personnel at participating sites enter information on demographics, clinical characteristics, in-hospital treatment, and discharge information for consecutive patients with stroke ≥18 years. 19 We included patients with a final discharge diagnosis of TIA as recorded by enrolling sites. Sites ascertained TIA cases using prospective clinical identification or retrospective identification based on International Classification of Diseases, Ninth Revision codes (435.x). To ensure only TIA patients with deficits because of ischemia were enrolled, sites were instructed to enter only those patients with TIA symptoms that were present on arrival. A time-based definition was then used to confirm a final TIA diagnosis for those patients with symptoms lasting <24 hours for whom no alternative diagnosis was identified. The registry contains information on TIA patients with acute symptoms at the time of emergency medical services (EMSs) activation or at the time of their presentation to the hospital where they were subsequently admitted, but does not contain information on nonhospitalized patients with TIA.
To obtain longitudinal outcomes, we used a previously validated deterministic matching technique to link in-hospital data from GWTG-Stroke to CMS claims data. 18 We used a set of indirect patient identifiers to link data from 108 527 patients with TIA admitted to 1326 GWTG-Stroke hospitals from 2003 to 2008 to CMS inpatient (part A) claims. We excluded patients who were not linked to CMS data or nonindex cases (n=9145); patients who were transferred out, discharged to hospice, died before discharge, or did not have a documented discharge destination (n=3471); patients who were receiving comfort measures only before discharge (n=435); patients not enrolled in CMS fee-for-service at hospital discharge (n=4721); patients admitted after 2008 (n=22 690); and patients with a CMS discharge date after 2008 (n=173). After these exclusions, our final analysis population comprised 67 892 patients with TIA from 1142 GWTG-Stroke hospitals. A previous analysis has demonstrated that Medicare-linked GWTG patients with ischemic stroke are representative of the broader Medicare population. 20 Compared with patients in the final study population, excluded patients were on average, more likely to be ambulatory before admission and more likely to have a history of heart failure and previous stroke/TIA.
Guideline-Directed Care
We evaluated the receipt of 5 individual performance measures recommended for patients with TIA, which were a subset of standardized performance measures jointly released by the American Heart Association/American Stroke Association, the Centers for Disease Control and Prevention's Coverdell Registry, and the Joint Commission Primary Stroke Center Certification program. These process-based metrics have been selected as primary targets for quality improvement in GWTG-Stroke and have been endorsed by the National Quality Forum. 21 Full specifications for each measure have been published. 22, 23 Performance metrics are calculated among patients without contraindications. In addition to the receipt of individual care metrics, we examined a global quality of care metric, called defect-free care (DFC), which is a binary patient-level metric representing receipt of all the performance metrics for which the patient was eligible. DFC was only calculated for those patients who were eligible for at least 1 quality of care metric.
Adverse Clinical Outcomes
The primary adverse clinical outcome of interest in this analysis was hospitalization for acute ischemic stroke during the 1 year after hospitalization and discharge for TIA. We searched CMS inpatient claims for International Classification of Diseases, Ninth Revision discharge codes consistent with ischemic stroke (International Classification of Diseases, Ninth Revision 433.x1-434.x1) during the year after TIA hospitalization. We excluded International Classification of Diseases, Ninth Revision code 436.x because it is not possible to distinguish ischemic stroke from hemorrhagic stroke for patients with a diagnosis code of 436.x. We also explored the association between quality of care and several secondary adverse clinical outcomes, including mortality and major adverse cardiovascular events, which were ascertained from CMS denominator files ( 
WHAT IS KNOWN
• Patients with transient ischemic attack are at high risk for ischemic stroke during the year after discharge. • Guideline-directed care may reduce the risk of ischemic stroke, but there is variation in delivery of this care across hospitals.
WHAT THE STUDY ADDS
• We created a risk score to identify patients with transient ischemic attack at increased risk for ischemic stroke from readily available clinical variables. • We found that transient ischemic attack patients with the highest estimated risk of ischemic stroke were least likely to receive defect-free care, largely because of lack of statin treatment. • Defect-free care was not associated with 1-year ischemic stroke risk but was associated with lower mortality risk.
Statistical Analysis
We estimated unadjusted 1-year risk of ischemic stroke, mortality, and the composite end point using cumulative incidence and Kaplan-Meier estimates. To create the GWTG Ischemic Stroke after TIA Risk Score, we created a multivariable Cox proportional hazards model of factors associated with ischemic stroke ≤1 year after TIA hospitalization. Follow-up was censored at death (n=6922) or loss of CMS eligibility (n=2237). We further estimated relationships with incidence of ischemic stroke using the Fine-Gray model for competing risks, where death is a competing risk for ischemic stroke. 24 Follow-up was still censored at loss of CMS eligibility. We identified a list of candidate covariates for the ischemic stroke readmission models based on existing evidence and biological plausibility. The full list of candidate covariates used to create the model is available in Table I in the Data Supplement. To select a final associative model, the data set was divided into equal-sized test and validation cohorts. In the test cohort, we used backward selection with a stay criterion of P=0.05. The fitted model was then applied to the validation cohort; model performance was evaluated with the c-statistic and the magnitude and direction of individual regression coefficients was compared. From the Fine-Gray model, we report subdistribution hazard ratios with 95% confidence intervals and P values. We also report cause-specific hazard ratios with confidence intervals and P values from the regression censoring at death. In a similar fashion, we generated a model for ischemic stroke admission during a 30-day period. After creating the risk score, we assessed the relationship between global DFC during the index TIA hospitalization and 1-year clinical outcomes, including ischemic stroke, all-cause mortality, and major adverse cardiovascular events. Furthermore, we sought to assess if the relationship between DFC and outcomes was modified by estimated ischemic stroke risk, which was estimated from the aforementioned Fine-Gray association model, with patients categorized by quintiles.
Cox proportional hazards models estimated the overall association between DFC and 1-year outcomes. Subdistribution and causespecific estimates are provided as appropriate, but are equivalent when the end point includes mortality. In the Cox models testing, the association between DFC and 1-year outcomes, we included indicator variables for DFC, risk score quintiles, and interaction between the 2. Then, we obtained the hazard ratio for DFC at each level of risk score quintile. None of the interactions were significant in the models. As a sensitivity analysis, we examined the association among patients without a history of previous stroke or TIA and we also evaluated 30-day outcomes.
All presented P values are 2-sided, with P<0.05 being considered significant. Missingness was <5% for all variables, except for medical history (missing for 6.5% of the total study population). To assess associations with risk of ischemic stroke, missing values were imputed to the most common response observed in the nonmissing data. For outcomes models, patients with missing information on DFC or clinical outcomes were excluded. Sites participating in the GWTG-Stroke program were required to comply with local regulatory guidelines and, where required, to obtain approval from local institutional review boards before entering patient data. Quintiles, Inc is the data collection coordination center for the American Heart Association/American Stroke Association Get With The Guidelines programs. Data linkage and analyses were approved by the Duke University Medical Center Institutional Review Board and performed at the Duke Clinical Research Institute (Durham, NC) under an existing data use agreement. All statistical analyses were performed using SAS software version 9.2 (SAS Institute, Inc, Cary, NC).
Results
The overall risk of ischemic stroke during the 1-year period after TIA hospitalization was 5.3%. The overall risk for mortality was 11.8% and major adverse cardiovascular events was 25.8%. The distribution of baseline characteristics by occurrence of ischemic stroke within 1 year is shown in Table 1 . Compared with patients who did not have ischemic stroke, those who did experience an ischemic stroke hospitalization during the 12 months of follow-up were more likely to be older, black, and smokers; have higher rates of comorbidities, including coronary disease/previous myocardial infarction, diabetes mellitus, peripheral vascular disease, heart failure, and previous stroke. Discharge characteristics of the study population by occurrence of ischemic stroke within 1 year are shown in Table 2 . Patients with TIA who were hospitalized for ischemic stroke in the year after discharge had lower rates of aspirin prescription at discharge and higher rates of antihypertensives and clopidogrel prescription than those who did not. Patients experiencing an ischemic stroke were also less likely to have been discharged to home, but more likely to have been discharged to a skilled nursing facility or inpatient rehabilitation.
GWTG Ischemic Stroke After TIA Risk Score
The final set of variables retained in the GWTG Ischemic Stroke after TIA Risk Score model is shown in Table 3 . White race, history of dyslipidemia, and ability to ambulate independently at discharge were associated with a decreased likelihood of 1-year admission for new ischemic stroke. Factors associated with an increased risk of ischemic stroke included age, atrial fibrillation, history of previous stroke or TIA, coronary artery disease/myocardial infarction, diabetes mellitus, smoking, and hospital arrival mode. The risk of ischemic stroke increased sequentially by risk score quintile (1st=2.7%, 2nd=3.9%, 3rd=5.1%, 4th=5.4%, and 5th=7.4%). The overall c-statistic for the final ischemic stroke risk model indicated moderate discrimination (c-statistic=0.606). In a sensitivity analysis, we found similar model discrimination for ischemic stroke at 30 days (c-statistic=0.572).
Outcomes by Risk Score Quintile
The Figure shows receipt rates of individual TIA quality measures within each ischemic stroke risk score quintile. Antithrombotic use at hospital day 2 and at antithrombotic use at discharge were high (>98%) for patients in all risk score quintiles. Rates of receipt of anticoagulation for atrial fibrillation and smoking cessation counseling were also similar across quintiles. Patients with a lower estimated ischemic stroke risk were more likely to receive statins than those with a higher estimated ischemic stroke risk. We observed an inverse association between receipt of the composite DFC metric and increasing ischemic stroke risk score, with less receipt of DFC among high-risk patients. This association was largely driven by the lower use of statins at discharge in patients with higher ischemic stroke risk scores. Table 4 displays the associations between the receipt of DFC and ischemic stroke, in addition to secondary adverse clinical outcomes of all-cause mortality, and the composite end point of mortality, ischemic stroke, and readmission for cardiovascular events. In unadjusted models for the overall cohort, we observed a small inverse association between DFC and ischemic stroke, but this association was not statistically significant. We did not observe statistically significant associations between DFC and ischemic stroke when stratifying by estimated ischemic stroke risk quintiles. DFC was associated with significantly lower all-cause mortality during 1 year in unadjusted models. This association persisted after stratification on ischemic stroke risk quintiles ( Table 4 ). Receipt of DFC was also associated with significantly lower rates of the composite end point in unadjusted models compared with no DFC. This association persisted across quintiles of ischemic stroke risk, but was no longer significant for patients in risk quintiles 2 or 3. In our sensitivity analysis, we examined associations between DFC and 30-day ischemic stroke. In unadjusted analyses, DFC was associated with an increased risk of ischemic stroke within 30 days of discharge. With the exception of risk quintile 2, these results were no longer significant on stratification ( Table II in the  Data Supplement) .
Because patients with a history of previous stroke or TIA are at greater risk for adverse outcomes, we excluded these patients and repeated the regression analyses. We found that DFC was not associated with unadjusted risk of ischemic stroke during the year after discharge in patients with previous stroke or TIA (Table III in the Data Supplement). However, these results were only significant on stratification for patients in the 4th quintile of estimated ischemic stroke risk. DFC was associated with a significantly lower unadjusted risk of allcause mortality among patients with previous stroke or TIA. On stratification, DFC was associated with a significantly lower risk of all-cause mortality in all patients, except for those in the lowest quintile of estimated ischemic stroke risk. 
Discussion
During the 1 year after TIA, 5.7% of elderly patients were admitted to the hospital for new ischemic stroke. We found that (1) Patients with TIA who had an ischemic stroke during the year after hospital discharge were more likely to be black and have a higher comorbidity burden than patients who did not;
(2) treatment rates of antithrombotics by hospital day 2, antithrombotics at discharge, and smoking cessation counseling did not differ between patients who developed an ischemic stroke versus those who did not; (3) Patients with TIA in the highest quintile of estimated ischemic stroke risk were less likely to receive DFC than patients in lower risk quintiles, largely because of lower rates of statin treatment at discharge; and (4) receipt of DFC was associated with a slightly lower risk for ischemic stroke, but this association did not persist when stratifying on ischemic stroke risk score quintiles; nonetheless, the receipt of DFC was associated with lower 1-year mortality.
Patients with TIA are at high risk of ischemic stroke during the year after hospital discharge. [1] [2] [3] [4] [5] Identifying patients in the highest risk strata has significant potential to inform acute care delivery and post discharge follow-up patterns. Several validated risk stratification schemes have been proposed for classification of ischemic stroke risk after TIA. The California score was developed to predict ischemic stroke risk within 90 days of TIA using information on age, diabetes mellitus, symptom duration, weakness, and speech impairment. 2 The ABCD score used a nearly identical set of variables to predict 7-day ischemic stroke risk, replacing diabetes mellitus with hypertension. 25 The more recent unified ABCD 2 score combines the 2 variable sets by incorporating information on both diabetes mellitus and hypertension. 7 However, validation studies have produced mixed results. [26] [27] [28] The California score was derived from a single healthcare system, which may not be representative of the national TIA population. Furthermore, as noted by the study authors, the ABCD analytic population was small, so the power to detect significant associations was limited by the number of events occurring during follow-up (n=18 in 209 patients). Finally, each score requires information on symptom duration, which may be unreliable or unavailable at the time of risk assessment. In contrast to existing scores, our score was developed in a large, national patient population and uses variables which are readily available to the clinician to support prediction of ischemic stroke after discharge.
Results from our risk association model are largely consistent with previous work examining factors predictive of readmission after a cerebrovascular event. Previous studies have reported associations of similar magnitude and direction as those we report here for diabetes mellitus, previous MI, black race, and age. 29, 30 We also found a positive association between EMSs arrival during the original TIA episode and subsequent risk of ischemic stroke. Previous work has reported increasing use of EMSs among patients with more severe events. 31 In the case of TIA, it is possible that EMSs was more likely to be activated in the presence of a motor/speech deficit versus a sensory or visual TIA. Because TIA presenting with motor or speech deficits is associated with higher recurrent stroke risk, 32, 33 EMSs use may therefore be correlative with adverse clinical outcomes, such as future ischemic stroke and allcause mortality.
In addition to baseline patient characteristics, a growing body of evidence suggests that delivery of optimal care during initial hospitalization may influence risk of stroke admission. In a systematic review of secondary prevention strategies after vascular events, Hackam et al 32 reported that the use of a comprehensive set of 5 prevention strategies (ie, diet, exercise, aspirin, statins, and antihypertensive medication) among survivors of stroke or TIA would result in a 5-year cardiovascular risk reduction of 80%. 2 We found that patients with the highest estimated ischemic stroke risk were less likely to receive evidence-based care metrics than lower risk patients. This risk-treatment mismatch has been previously reported for other acute cardiovascular populations, including heart failure 13 and myocardial infarction. 14 The undertreatment of higher risk patients may reflect provider uncertainty about the risk/benefit ratio in these patients, who are generally underrepresented in randomized clinical trials. In addition, retrospectively collected data may yield incomplete information on potentially confounding clinical and functional variables that the clinician must use when selecting appropriate therapies (eg, frailty). In this analysis, we calculated receipt of evidence-based care metrics on the subset of patients who were eligible for each metric. Yet, in addition to broad eligibility criteria, optimal clinical decision-making incorporates patient preferences and clinical judgment-factors that are not easily quantifiable in observational analyses. Recent evidence suggests that the treatment gap between high-and low-risk patients may be narrowing. 14 Although some treatment differences persist, even the lowest rates of evidence-based care delivery are high in absolute terms.
We did not find significant associations between DFC and risk of ischemic stroke after stratification on GWTG Ischemic Stroke after TIA Risk Score. There are many possible explanations for this finding. First, as the majority of GWTG-Stroke data is captured via retrospective review, inadequate documentation (ie, recording receipt of the measure when it was not delivered, or failing to document the measure when it was received) could attenuate associations between individual or global metrics and clinical outcomes. Second, as discharge medication metrics reflect intention to treat, associations with long-term postdischarge outcomes may be influenced by suboptimal adherence and other treatments prescribed after discharge. Finally, as adherence to guideline-directed care in this population was high overall, there may have been insufficient variation in quality of care to detect differences in longterm outcomes. Importantly, we found lower risk of all-cause mortality among patients who received DFC compared with those who did not, suggesting that delivery of guidelinedirected care has survival benefits in the year after hospitalization for TIA.
Our study had several limitations. First, as with all observational analyses, we cannot exclude the possibility of residual confounding. Second, as this analysis is limited to CMS patients, our results may not be generalizable to younger patients with TIA. Third, information on medication use after discharge was not available, so we were unable to assess potential effects of differential adherence by risk score subgroups on adverse outcomes. In addition, as DFC is a composite measure, it may be influenced by variation in the use of a single measure, as was found in this study with statin prescription; however, we were underpowered to examine associations between individual performance metrics and outcomes within quintiles of estimated risk. Fourth, we did not have information on motor or speech symptoms, which were predictive of ischemic stroke risk in the ABCD 2 score. Fifth, although TIA case ascertainment in GWTG-Stroke is designed to enhance specificity, it is possible that some patients with minor strokes or those with symptoms because of nonischemic events were misclassified as TIA. Approximately 64% of patients with TIA are hospitalized. 34 Because GWTG-Stroke is hospital-based and patients with TIA may present in other healthcare settings (eg, primary care provider offices or health clinics), patients seen at participating hospitals may not be representative of the nonhospitalized population with TIA, particularly in the recent era of increasing observation use and specialized TIA outpatient clinics. Finally, given the moderate predictive performance of this and other scores to predict ischemic stroke after TIA, further exploration of genetic, biological, and socioeconomic predictors in this high-risk population is warranted.
In conclusion, we found that patients who had an ischemic stroke within 1 year of a TIA hospitalization had a greater comorbidity burden than patients who did not. TIA patients with a high baseline risk of ischemic stroke are less likely to receive DFC than low-risk patients, largely because of a lack of statin treatment. DFC was not associated with a 1-year risk of ischemic stroke overall, nor when stratified by estimated ischemic stroke risk, but was associated with a lower risk of 1-year mortality.
